

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 016303-007120US

PATENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

SEP 30 1999


TECH CENTER 1600/2900

On

9-24-99

TOWNSEND and TOWNSEND and CREW LLP

*Grinda Shaffer*



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

JOSHI *et al.*

Application No.: 09/295,663

Filed: April 21, 1999

For: COMBINATION THERAPY  
USING NUCLEIC ACIDS AND  
CONVENTIONAL DRUGS

Examiner: Lee, Gai (Jennifer) Mi

Art Unit: 1632

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed September 1, 1999, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

Please cancel the present "SEQUENCE LISTING" and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 and 2, at the end of the application.